Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 121 to 135 of 1505 results for patients and public

  1. CaRi-Heart for predicting cardiac risk in adults with suspected coronary artery disease (CAD)

    In development Reference number: GID-HTE10085 Expected publication date: TBC

  2. AI software for electroencephalogram (EEG) interpretation in epilepsy

    In development Reference number: GID-HTE10086 Expected publication date: TBC

  3. Intravenous fluid therapy in adults in hospital (CG174)

    This guideline covers the general principles for managing intravenous (IV) fluid therapy in hospital inpatients aged 16 and over with a range of conditions. It aims to help prescribers understand the optimal amount and composition of IV fluids to be administered and the best rate at which to give them, to improve fluid prescribing and outcomes among people in hospital. It does not cover pregnant women, and those with severe liver or renal disease, diabetes or burns.

  4. Type 2 diabetes: prevention in people at high risk (PH38)

    This guideline covers how to identify adults at high risk of type 2 diabetes. It aims to remind practitioners that age is no barrier to being at high risk of, or developing, the condition. It also aims to help them provide those at high risk with an effective and appropriate intensive lifestyle-change programme to prevent or delay the onset of type 2 diabetes. The recommendations in this guideline can be used alongside the NHS Health Check programme .

  5. Acalabrutinib and venetoclax with or without obinutuzumab for untreated chronic lymphocytic leukaemia [ID6232]

    In development Reference number: GID-TA11230 Expected publication date:  22 April 2026

  6. Sexual health (QS178)

    This quality standard covers sexual health, focusing on preventing sexually transmitted infections (STIs). It describes high-quality care in priority areas for improvement.

  7. Who can register as a stakeholder?

    Find out more about the types of organisations that can register to be a stakeholder at NICE.

  8. Clostridioides difficile infection: antimicrobial prescribing (NG199)

    This guideline sets out an antimicrobial prescribing strategy for managing Clostridioides difficile infection in adults, young people and children aged 72 hours and over in community and hospital settings. It aims to optimise antibiotic use and reduce antibiotic resistance. The recommendations do not cover diagnosis.

  9. Encorafenib with binimetinib for treating BRAF V600E mutation-positive advanced non-small-cell lung cancer [ID6177]

    In development Reference number: GID-TA11140 Expected publication date: TBC

  10. Oesophago-gastric cancer: assessment and management in adults (NG83)

    This guideline covers assessing and managing oesophago-gastric cancer in adults, including radical and palliative treatment and nutritional support. It aims to reduce variation in practice through better organisation of care and support, and improve quality of life and survival by giving advice on the most suitable treatments depending on cancer type, stage and location.

  11. HIV testing: increasing uptake among people who may have undiagnosed HIV (NG60)

    This guideline covers how to increase the uptake of HIV testing in primary and secondary care, specialist sexual health services and the community. It describes how to plan and deliver services that are tailored to the local prevalence of HIV, promote awareness of HIV testing and increase opportunities to offer testing to people who may have undiagnosed HIV.

  12. Medical technologies advisory committee members

    Read the biographies of our medical technologies advisory committee members.

  13. Medical technologies advisory committee members

    Read the biographies of our medical technologies advisory committee members.

  14. Rozanolixizumab for treating antibody-positive generalised myasthenia gravis [ID5092]

    In development Reference number: GID-TA10994 Expected publication date: TBC

  15. Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma [review of TA658] [ID4067]

    In development Reference number: GID-TA10979 Expected publication date:  11 March 2026